Results 121 to 130 of about 9,231 (199)

No association between the XPD Lys751Gln (rs13181) polymorphism and disease phenotype or leukemic transformation in primary myelofibrosis

Haematologica, 2013
Valentina Poletto, Laura Villani, Paolo Catarsi, Rita Campanelli, Margherita Massa, Alessandro M. Vannucchi, Vittorio Rosti, Giovanni Barosi   +7 more
doaj   +1 more source

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia

Cancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background This clinical trial sought to determine whether SL‐172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher‐risk myelodysplastic syndrome (HR‐MDS) or acute myeloid leukemia (AML). Methods Dose escalation: doses of 1, 3, and 6 mg/kg SL‐172154 was evaluated as monotherapy or in combination ...
Naval G. Daver, Amer M. Zeidan, Anthony S. Stein, Joshua F. Zeidner, Keri Maher, Emily Curran, Dale Bixby, Wanxing Chai‐Ho, Maximilian Stahl, Karen W. L. Yee, Don Stevens, Sawa Ito, Jana Reynolds, Patrick Medd, Emma Searle, Andrew Sochacki, Mary Lynn Savoie, Steven Green, Kazunobu Kato, Robert Hernandez, Simon Metenou, Bo Ma, Lini Pandite, Taylor H. Schreiber, David A. Sallman   +24 more
wiley   +1 more source

Myelofibrosis

Hematology, 2014
Claire, Harrison, Donal, McLornan
openaire   +2 more sources

The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO)

International Journal of Cancer, Volume 159, Issue 7, Page 1633-1641, 1 October 2026.
ABSTRACT The recently published ONKOPEDIA guideline on myelofibrosis, issued under the auspices of the German Society of Hematology and Oncology (DGHO), provides an updated, evidence‐based framework for the diagnosis and management of this rare, chronic myeloproliferative neoplasm.
Martin Griesshammer, Haifa Kathrin Al‐Ali, Gabriela M. Baerlocher, Konstanze Döhner, Steffen Koschmieder, Nicolaus Kröger, Petro E. Petrides, Dominik Wolf, Florian H. Heidel   +8 more
wiley   +1 more source

Primary Myelofibrosis - 2

, 2018
An image from a peripheral blood smear showing RBC poikilocytosis: tears, elliptocytes, and schistocytes in a patient with primary myelofibrosis. A large platelet (top), Neutrophil, and nucleated RBC (center) are also seen (50X oil immersion)
To, Michelle, Kwon, Gloria
core   +1 more source

Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia

The Journal of Clinical Pharmacology, Volume 66, Issue 10, October 2026.
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Albert Qin, Lucia Masarova, Haoqi Chen, Zhijian Xiao, Jie Jin, Harinder Gill, Brandi N Reeves, Firas El Chaer, Keita Kirito, Norio Komatsu, Ghaith Abu‐Zeinah, Kazuya Shimoda, Oleh Zagrijtschuk, Toshiaki Sato, Daoxiang Wu, Lei Wu, Xia Su, Yucheng Gao, Jie Cui, Lei Zhang, Ruben A Mesa   +20 more
wiley   +1 more source

Intraspinal extramedullary haematopoiesis in a patient with myelofibrosis

, 2002
A 54-year-old patient with myelofibrosis developed paresis of the legs, and bladder dysfunction due to extramedullary haematopoiesis in the spinal channel. He was given palliative radiotherapy but died shortly afterwards.
van de Loosdrecht, AA, Daenen, SMGJ, de Haas, KP   +2 more
core   +1 more source

Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Background TP53 mutations (TP53m) are uncommon in chronic‐phase Ph–negative myeloproliferative neoplasms but become enriched in myelofibrosis (MF) and accelerated/blast phase myeloproliferative (AP/BP‐MPN). Their prevalence, allelic distribution, and phase‐stratified outcomes have not been systematically synthesized.
Mahmood Aldapt, Rasha Kaddoura, Ahmed O. Saleh, Mostafa Najim, Ahmad Salem, Abdulrahman F. Al‐Mashdali, Bassam Muthanna, Ruba Adel Aweer, Marrita Rabadi, Shehab F. Mohamed   +9 more
wiley   +1 more source

Myelofibrosis associated with severe vitamin D deficiency rickets

, 2005
Myelofibrosis is a rare disorder in childhood. In this report, we present the case of a 6-month-old infant with myelofibrosis due to severe vitamin D deficiency rickets.
Balkan, C, Nese, N, Ersoy, B, Ersoy B., ERSOY, BETÜL, Nese N., Balkan, C., Balkan C., Nese, N.   +8 more
core   +1 more source

When Liver Disease Misleads the Diagnosis: Two Cases of TAFRO Syndrome With Porto‐Sinusoidal Vascular Disease

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Background TAFRO syndrome is a rare inflammatory disorder whose hepatic manifestations may mimic decompensated cirrhosis. Cases: We report two women with TAFRO syndrome associated with portal‐sinusoidal vascular disorder (PSVD), a rare cause of non‐cirrhotic portal hypertension. In both cases, liver biopsy excluded cirrhosis and confirmed PSVD.
Laura Dassy, Fanny Poletti, Kaoutar Hafraoui, Marie Lejeune, Joan Somja, Patrick Collins, Julien Guiot, Ivan Theate, Jo Caers, Jean Delwaide, Astrid Marot, Virginie Putzeys, Gaëlle Vertenoeil   +12 more
wiley   +1 more source